Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
The eosinophilic esophagitis market is witnessing steady growth, primarily driven by the increasing awareness leading to standardized diagnosis and high relapse rates that continue to fuel ongoing treatment demand. Additionally, the expected launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), and others will further propel the market growth.
Recently published Eosinophilic Esophagitis Market Insights report includes a comprehensive understanding of current treatment practices, eosinophilic esophagitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Eosinophilic Esophagitis Market Summary
Discover eosinophilic esophagitis market size 2036 @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market
Key Factors Driving the Growth of the Eosinophilic Esophagitis Market
Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight, said that emerging therapies that reduce dosing frequency or improve ease of administration may capture patients with adherence challenges or inadequate response to current options.
Eosinophilic Esophagitis Market Analysis
Learn more about the EoE approved drugs list @ Eosinophilic Esophagitis Treatment Market
Eosinophilic Esophagitis Competitive Landscape
Some of the eosinophilic esophagitis drugs under development include Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), Solrikitug (NSI-8226) (Uniquity Bio), ESO-101 (EsoCap AG), Viaskin milk (DBV-135) (DBV Technologies), EP-104GI (Eupraxia Pharmaceuticals), and others.
AstraZeneca and Amgen’s Tezepelumab is a novel monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP), an upstream epithelial cytokine that plays a central role in triggering and sustaining multiple inflammatory pathways. By inhibiting TSLP, tezepelumab addresses the underlying drivers of allergic, eosinophilic, and other epithelial inflammatory responses associated with conditions such as severe asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), along with other related disorders.
In its Q3 2025 update presented in November 2025, AstraZeneca indicated that results from the CROSSING trial evaluating tezepelumab in Eosinophilic Esophagitis (EoE) are expected in the latter half of 2026. Earlier, in October 2021, the therapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for EoE treatment.
Ellodi Pharmaceuticals’ APT-1011 is an innovative, once-daily orally disintegrating tablet (ODT) developed to deliver fluticasone propionate directly to the esophageal lining, providing localized anti-inflammatory effects while minimizing systemic exposure. Following the successful outcomes of the FLUTE 1 (Phase IIb) and FLUTE 2 (Phase III) trials, the FLUTE 3 study, a second Phase III trial, is currently underway.
In May 2024, Ellodi Pharmaceuticals presented findings from the FLUTE-2 Phase III trial at Digestive Disease Week (DDW) 2024 Annual Scientific Meeting, highlighting the efficacy of APT-1011 in EoE. The therapy has been granted Orphan Drug Designation by both the FDA and the European Medicines Agency, along with Fast Track Designation (FTD) from the FDA in 2021. These designations were supported by clinical data demonstrating histological remission, symptomatic relief after 12 weeks of induction therapy, and sustained benefits over long-term treatment.
Revolo Biotherapeutics’ IRL201104 represents a first-in-class peptide designed to re-establish immune balance by modulating both regulatory and effector immune pathways. In August 2025, Revolo Biotherapeutics announced plans to fast-track the clinical development of a sublingual tablet formulation of IRL201104, administered under the tongue.
The anticipated launch of these emerging eosinophilic esophagitis therapies are poised to transform the Eosinophilic Esophagitis market landscape in the coming years. As these cutting-edge eosinophilic esophagitis therapies continue to mature and gain regulatory approval, they are expected to reshape the eosinophilic esophagitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about novel treatments for EoE, visit @ Eosinophilic Esophagitis Medication
Recent Developments in the Eosinophilic Esophagitis Market
What is Eosinophilic Esophagitis?
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus characterized by the accumulation of eosinophils in the esophageal lining. It is primarily triggered by food allergens and, in some cases, environmental allergens, leading to symptoms such as difficulty swallowing, food impaction, chest discomfort, and persistent heartburn that does not respond well to conventional acid-suppressive therapies. Over time, untreated EoE can cause esophageal remodeling, including fibrosis and strictures, which further impair swallowing. The condition is commonly associated with other atopic disorders such as asthma, allergic rhinitis, and eczema. Diagnosis typically involves endoscopic evaluation and biopsy, while management includes dietary modifications, proton pump inhibitors, and topical corticosteroids to reduce inflammation and prevent disease progression.
Eosinophilic Esophagitis Epidemiology Segmentation
The eosinophilic esophagitis epidemiology section provides insights into the historical and current eosinophilic esophagitis patient pool and forecasted trends for the leading markets. In the EU4 and the UK, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 395,000 cases reported in 2025.
The eosinophilic esophagitis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
Download the report to understand current treatment for eosinophilic esophagitis @ Eosinophilic Esophagitis Treatment Options
Scope of the Eosinophilic Esophagitis Market Report
Discover more about eosinophilic esophagitis drugs in development @ Eosinophilic Esophagitis Clinical Trials
Table of Contents
Related Reports
Eosinophilic Esophagitis Epidemiology
Eosinophilic Esophagitis Epidemiology Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted EoE epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Eosinophilic Esophagitis Clinical Trial Analysis Pipeline
Eosinophilic Esophagitis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic esophagitis companies, including Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion, Quorum Innovations, Serpin Pharma, RAPT Therapeutics, and others.
Eosinophilic Disorder Market
Eosinophilic Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic disorder companies including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, and others.
Eosinophilic Disorder Clinical Trial Analysis
Eosinophilic Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic disorder companies, including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, and others.
Asthma Market
Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.